Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis

Research output: Contribution to journalJournal articleResearchpeer-review

  • Craig Leonardi
  • Robert Matheson
  • Zachariae, Claus
  • Gregory Cameron
  • Linda Li
  • Emily Edson-Heredia
  • Daniel Braun
  • Subhashis Banerjee
Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment.
Original languageEnglish
JournalNew England Journal of Medicine
Issue number13
Pages (from-to)1190-9
Number of pages10
Publication statusPublished - 2012

ID: 40205805